Invitae (OTC: NVTA)
Some price data may be temporarily unavailable.
Key Data Points
Invitae Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Invitae Company Info
Invitae offers medical genetics testing for a variety of diseases, disorders, and pediatric conditions.
News & Analysis
Is Invitae Stock a Buy Now?
Invitae shares have lost more than 80% over the past year and a half.
3 Things About Invitae Every Smart Investor Knows
The last two years have been tumultuous, and there are no calm waters in sight.
Is Invitae Stock a Buy Now?
Invitae shares have dropped more than 60% this year.
Why Invitae Stock Popped Today
Invitae just received a key marketing authorization from the FDA for a first-of-its-kind cancer test.
Invitae Stock Analysis: Buy, Sell, or Hold?
The genetic testing company is reducing costs to improve margins.
Cathie Wood Is Betting on This Struggling Stock. Should You?
The stock has lost 90% in about 18 months.
Why Invitae Stock Is Crashing Today
The bad news continues to pour in for this beaten-down genetic testing stock.
Down 96% Is Invitae Stock a Buy?
The innovative medical services company is making adjustments to improve the bottom line.
Financial Health
General
Q3 2023 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q3 2023 | YoY Change |
---|
Liabilities
Q3 2023 | YoY Change |
---|
Ratios
Q3 2023 | YoY Change |
---|
Cash Flow
Q3 2023 | YoY Change |
---|
Valuation
Q2 2023 | Q3 2023 |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.